Livzon Pharmaceutical Group Inc. (HKG:1513)

HKG:1513 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Jan 1, 2021
Operating Revenue	11,638	11,701	12,326	12,524	11,928	10,463
Other Revenue	111.73	111.73	104.45	105.89	135.88	57.34
Revenue	11,750	11,812	12,430	12,630	12,064	10,520
Revenue Growth (YoY)	-4.16%	-4.97%	-1.58%	4.69%	14.67%	12.10%
Cost of Revenue	4,218	4,249	4,772	4,577	4,309	3,744
Gross Profit	7,532	7,564	7,658	8,053	7,754	6,777
Selling, General & Admin	3,754	3,869	4,255	4,545	4,548	3,740
Research & Development	1,011	1,033	1,335	1,427	1,146	884.1
Other Operating Expenses	146.8	120.33	133.07	143.97	135.87	122.94
Operating Expenses	4,917	5,027	5,736	6,121	5,837	4,747
Operating Income	2,615	2,536	1,921	1,932	1,917	2,029
Interest Expense	-80.7	-88.61	-102.09	-97.55	-84	-25.31
Interest & Investment Income	256.11	265.34	429.98	359.25	251.81	323.19
Currency Exchange Gain (Loss)	0.94	0.94	10.23	56.68	-4.28	-41.56
Other Non Operating Income (Expenses)	-4.14	-6.98	-4.42	-6.37	-4.01	-5.89
EBT Excluding Unusual Items	2,787	2,707	2,255	2,244	2,077	2,280
Gain (Loss) on Sale of Investments	-16.16	-15.44	-25.65	-75.27	-23.03	8.81
Gain (Loss) on Sale of Assets	44.81	45.2	-0.17	0.86	7.03	-1.07
Asset Writedown	-22.12	-19.86	-2.43	-13.99	-6.15	-6.9
Other Unusual Items	126.56	89.08	155.76	174.68	191.12	208.76
Pretax Income	2,920	2,806	2,383	2,331	2,246	2,489
Income Tax Expense	528.25	501.66	485.07	374.97	293.59	358.11
Earnings From Continuing Operations	2,392	2,304	1,898	1,956	1,952	2,131
Minority Interest in Earnings	-302.07	-243.39	56.05	-46.17	-176.42	-416.42
Net Income	2,090	2,061	1,954	1,909	1,776	1,715
Net Income to Common	2,090	2,061	1,954	1,909	1,776	1,715
Net Income Growth	5.58%	5.50%	2.32%	7.53%	3.54%	31.62%
Shares Outstanding (Basic)	911	920	929	935	935	936
Shares Outstanding (Diluted)	911	920	931	936	936	939
Shares Change (YoY)	-2.04%	-1.10%	-0.56%	-0.04%	-0.25%	0.41%
EPS (Basic)	2.29	2.24	2.10	2.04	1.90	1.83
EPS (Diluted)	2.29	2.24	2.10	2.04	1.90	1.83
EPS Growth	7.74%	6.64%	2.94%	7.47%	3.73%	31.66%
Free Cash Flow	2,225	2,409	2,428	1,833	593.23	1,514
Free Cash Flow Per Share	2.44	2.62	2.61	1.96	0.63	1.61
Dividend Per Share	1.100	1.100	1.350	1.600	1.300	1.250
Dividend Growth	-18.52%	-18.52%	-15.63%	23.08%	4.00%	8.70%
Gross Margin	64.11%	64.03%	61.61%	63.76%	64.28%	64.41%
Operating Margin	22.25%	21.47%	15.46%	15.30%	15.89%	19.29%
Profit Margin	17.79%	17.45%	15.72%	15.12%	14.72%	16.30%
Free Cash Flow Margin	18.94%	20.39%	19.54%	14.51%	4.92%	14.39%
EBITDA	3,097	3,086	2,740	2,563	2,342	2,421
EBITDA Margin	26.36%	26.12%	22.05%	20.29%	19.41%	23.01%
D&A For EBITDA	481.92	549.3	818.8	630.56	425.02	391.69
EBIT	2,615	2,536	1,921	1,932	1,917	2,029
EBIT Margin	22.25%	21.47%	15.46%	15.30%	15.89%	19.29%
Effective Tax Rate	18.09%	17.88%	20.36%	16.09%	13.07%	14.38%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.